ECSP19055179A - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents

Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)

Info

Publication number
ECSP19055179A
ECSP19055179A ECSENADI201955179A ECDI201955179A ECSP19055179A EC SP19055179 A ECSP19055179 A EC SP19055179A EC SENADI201955179 A ECSENADI201955179 A EC SENADI201955179A EC DI201955179 A ECDI201955179 A EC DI201955179A EC SP19055179 A ECSP19055179 A EC SP19055179A
Authority
EC
Ecuador
Prior art keywords
ahr
aryl hydrocarbon
hydrocarbon receptor
modulating compounds
compounds
Prior art date
Application number
ECSENADI201955179A
Other languages
English (en)
Inventor
Ulrich Deuschle
Christoph Steeneck
Thomas Hoffmann
Michael Albers
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of ECSP19055179A publication Critical patent/ECSP19055179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. La invención además se refiere al uso de los compuestos para el tratamiento y/o profilaxis de enfermedades y/o condiciones a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.
ECSENADI201955179A 2017-02-01 2019-07-31 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) ECSP19055179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17000157 2017-02-01

Publications (1)

Publication Number Publication Date
ECSP19055179A true ECSP19055179A (es) 2019-08-30

Family

ID=57960222

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201955179A ECSP19055179A (es) 2017-02-01 2019-07-31 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)

Country Status (26)

Country Link
US (1) US11376241B2 (es)
EP (1) EP3577115B1 (es)
JP (1) JP2020505467A (es)
KR (1) KR20190113902A (es)
CN (1) CN110234650A (es)
AR (1) AR110790A1 (es)
AU (1) AU2018216955B2 (es)
BR (1) BR112019015704A2 (es)
CA (1) CA3051034A1 (es)
CL (1) CL2019002112A1 (es)
CO (1) CO2019007882A2 (es)
CR (1) CR20190393A (es)
CU (1) CU20190067A7 (es)
EA (1) EA201991600A1 (es)
EC (1) ECSP19055179A (es)
IL (1) IL268082A (es)
JO (1) JOP20190176A1 (es)
MX (1) MX2019008993A (es)
NI (1) NI201900075A (es)
PE (1) PE20191479A1 (es)
PH (1) PH12019550136A1 (es)
SG (1) SG11201906959RA (es)
TW (1) TWI674260B (es)
UA (1) UA122746C2 (es)
UY (1) UY37590A (es)
WO (1) WO2018141855A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
EP4219495A1 (en) 2018-02-06 2023-08-02 Ideaya Biosciences, Inc. Ahr modulators
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
US12473262B2 (en) 2019-07-30 2025-11-18 Oregon State University Aryl hydrocarbon receptor activators
KR102351515B1 (ko) * 2019-12-17 2022-01-14 (주)수파드엘릭사 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
WO2021148628A1 (en) * 2020-01-23 2021-07-29 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
WO2022146920A1 (en) * 2020-12-28 2022-07-07 Celgene Corporation Heterocyclic compounds and their use for parasitic diseases
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
TW202425965A (zh) 2022-09-30 2024-07-01 日商科研製藥股份有限公司 縮環化合物及含有其之醫藥
EP4602034A2 (en) * 2022-10-14 2025-08-20 Oregon State University Selective modulators of ahr-regulated transcription and method for using such modulators to treat cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002500A1 (fr) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. Derive de 2-phenylindole
HUP9903330A2 (hu) 1996-11-19 2000-03-28 Amgen Inc. Gyulladásgátló hatású, aril- és heteroaril csoporttal szubsztituált kondenzált pirrolszármazékok, valamint ezeket tartalmazó gyógyászati készítmények
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7622466B2 (en) 2005-11-18 2009-11-24 Hoffman-La Roche Inc. Azaindole-2-carboxamide derivatives
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
ES2791684T3 (es) * 2009-11-02 2020-11-05 Ariagen Inc ITE para la intervención y erradicación del cáncer
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
SI2531501T1 (sl) * 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US10314810B2 (en) 2010-07-27 2019-06-11 Trustees Of Boston University Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
HK1207379A1 (en) 2012-10-17 2016-01-29 霍夫曼-拉罗奇有限公司 6-aminoindole derivatives as trp channel antagonists
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
MX2019008993A (es) 2019-12-19
CL2019002112A1 (es) 2019-12-20
IL268082A (en) 2019-09-26
US11376241B2 (en) 2022-07-05
AU2018216955A1 (en) 2019-08-01
JOP20190176A1 (ar) 2019-07-15
WO2018141855A1 (en) 2018-08-09
CU20190067A7 (es) 2020-03-04
CN110234650A (zh) 2019-09-13
AU2018216955B2 (en) 2020-09-17
CR20190393A (es) 2019-10-21
TWI674260B (zh) 2019-10-11
UY37590A (es) 2018-02-28
UA122746C2 (uk) 2020-12-28
JP2020505467A (ja) 2020-02-20
SG11201906959RA (en) 2019-08-27
TW201838991A (zh) 2018-11-01
NI201900075A (es) 2019-10-30
PH12019550136A1 (en) 2020-03-02
KR20190113902A (ko) 2019-10-08
CA3051034A1 (en) 2018-08-09
EP3577115A1 (en) 2019-12-11
EP3577115B1 (en) 2020-12-02
PE20191479A1 (es) 2019-10-16
CO2019007882A2 (es) 2019-10-09
US20210260045A1 (en) 2021-08-26
BR112019015704A2 (pt) 2020-04-07
AR110790A1 (es) 2019-05-02
EA201991600A1 (ru) 2020-03-10

Similar Documents

Publication Publication Date Title
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
CO2019007882A2 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
MX2018010564A (es) Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
MX2017014375A (es) Moduladores del ccr2.
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
UY35993A (es) Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina
UY36209A (es) Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX2020006355A (es) Pirrolidinamidas ii sustituidas.